CLEAR CELL RENAL CELL CARCINOMA

This study tested two drugs, pazopanib and bevacizumab, given in turns to people with advanced kidney cancer that had spread. The goal was to find the best dose and see if the combination helps control the disease. 51 patients took part, and the study looked at side effects and h…

This early-stage study tests a new drug called NYM096 for people with advanced clear cell kidney cancer that has spread. The drug is designed to find and treat cancer cells using a special imaging scan and targeted radiation. The study has two parts: first, using a low dose to se…

This study tests whether adding a radioactive drug (radium-223) to the standard treatment (cabozantinib) can improve outcomes for people with advanced kidney cancer that has spread to the bone. About 134 participants will receive either the combination or cabozantinib alone. The …

This study tests a personalized treatment plan for people with advanced kidney cancer. It combines two drugs: an immunotherapy (pembrolizumab) and a targeted therapy (axitinib). The dose of each drug is adjusted based on how the patient's tumor responds. The goal is to see if thi…

This early-phase trial tests the safety and best dose of a combination of two or three drugs (cabozantinib, nivolumab, and possibly ipilimumab) in people with advanced genitourinary cancers that have spread. About 152 adults with these cancers will participate. The goal is to fin…

This study tests a drug called adavosertib in 18 adults with advanced solid tumors that lack a working SETD2 gene. The drug works by blocking enzymes that cancer cells need to grow. The main goal is to see if the tumors shrink or stop growing.

This study tests whether the drug pazopanib can delay or prevent kidney cancer from returning in patients who have had all visible tumors removed by surgery. About 129 adults with advanced kidney cancer that spread to other parts of the body but showed no signs of disease after s…

This study tested the drug axitinib in 22 people with a type of kidney cancer (clear cell renal cell carcinoma) who needed surgery but had complex tumors that made it hard to remove only the cancerous part. The goal was to see if taking axitinib before surgery could shrink the tu…

This study tests a drug called ceralasertib, either alone or combined with olaparib or durvalumab, in people with advanced solid tumors like kidney, bladder, pancreatic, endometrial, and prostate cancers. The goal is to see if these combinations can shrink tumors or slow their gr…

This study tests if a shot (subcutaneous) of the drug nivolumab works as well as the standard IV infusion for people with advanced or spreading clear cell kidney cancer. About 681 participants who have already had other treatments will receive either the shot or the IV. The goal …

This study tests whether combining two drugs—nivolumab and a radioactive antibody called 177Lu-girentuximab—is safe and effective for people with advanced clear cell kidney cancer that has a specific protein (CAIX). Nine participants will receive the treatment to find the best do…

This study tests whether adding a supplement called Seleno-L methionine to the standard two-drug therapy (axitinib and pembrolizumab) is safe and works better for people with advanced clear cell kidney cancer. About 55 participants will receive the combination. The goal is to see…

This early-phase trial tests adding camu camu, a prebiotic fruit, to standard immunotherapy (nivolumab and ipilimumab) for people with advanced kidney cancer that has spread. The main goal is to find the safest dose and see how it affects gut bacteria. About 31 participants will …

This study tests a combination of two drugs—entinostat and aldesleukin—for people with kidney cancer that has spread. The goal is to find the safest dose and see if the combo can shrink tumors. About 47 adults with clear cell kidney cancer are taking part.

This study tests whether adding an experimental immune-boosting drug (anti-OX40 antibody) to the standard targeted therapy axitinib helps control advanced kidney cancer better than axitinib alone. About 62 adults whose cancer worsened after prior immunotherapy will receive either…

This early-phase study tests whether giving immunotherapy drugs (nivolumab alone or with bevacizumab or ipilimumab) before surgery is safe for people with kidney cancer that has spread. About 104 participants will receive these treatments to see how the body reacts and whether th…

This study tests whether the drug cabozantinib can shrink kidney tumors before surgery in people with locally advanced clear cell renal cell carcinoma. About 22 participants will receive cabozantinib before their operation. The goal is to see if the drug reduces tumor size and he…

This phase 3 trial tests whether adding the targeted therapy cabozantinib to standard immunotherapy (nivolumab and ipilimumab) helps people with advanced kidney cancer live longer. About 1,175 adults with untreated, metastatic clear cell renal cell carcinoma are participating. Th…

This study collects blood, urine, and tissue samples from 589 people to find new DNA markers that could help detect kidney and urinary tract cancers earlier. Researchers are looking for specific changes in DNA methylation that are unique to these cancers. The goal is to develop a…

This study was designed to see if a special PET/CT scan using a tracer called piflufolastat F 18 can better detect whether clear cell renal cell carcinoma (a type of kidney cancer) has spread. It aimed to find the best dose and timing for the scan and to see if the results change…

This study aims to understand how kidney tumors in people with von Hippel-Lindau (VHL) syndrome differ from one another and within the same tumor. Researchers will use advanced imaging, multiple biopsies, and lab-grown tumor models to map these differences. The goal is to gather …